Chronic Pancreatitis
Conditions
Brief summary
This study will assess cognitive behavioral therapy as an adjunct to conventional symptom control for patients with chronic pancreatitis.
Detailed description
All patients with chronic pancreatitis will be considered for participation in this study. Patients selected for participation will be evaluated 4 weeks prior to the first one-on-one therapy session. A baseline pain score will be assessed using the visual analog pain scale. Narcotic dosage and frequency as well as anti-emetic usage will be evaluated at this time. A pre-treatment quality of life score will be recorded using the SF-12® Patient Questionnaire. Patients will also be queried about the presence of nausea and reflux. After the pre-intervention evaluations are complete, patients will be randomized into one of two arms: treatment with cognitive behavioral therapy and narcotics as needed or treatment with conventional narcotic analgesics alone. Patients undergoing CBT intervention will participate in eight weekly therapy sessions. Follow-up assessments will be conducted six months and nine months after the last therapy session is completed. The patients will be evaluated based on pain score, narcotic dosage and frequency, anti-emetic usage, quality of life assessment, and pain related hospitalizations.
Interventions
BEHAVIORALCognitive Behavioral Therapy
Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
Sponsors
University of Louisville
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Patients will be randomized into one of two arms: treatment with cognitive behavioral therapy and narcotics as needed or treatment with conventional narcotic analgesics alone. Patients undergoing CBT intervention will participate in eight weekly therapy sessions.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient must be18 years of age 2. Diagnosed with chronic pancreatitis 3. Willing and able to comply with the protocol requirements 4. Able to comprehend and have signed the Informed Consent Form (ICF) to participate in the study
Exclusion criteria
1\. Participating in another clinical trial for the treatment of chronic pancreatitis at the time of screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence and severity of abdominal pain | 1 year | A visual analog scale will be used to measure patients pain pre- and post- intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life | 1 year | quality of life with be measured using the SF-12® Patient Questionnaire |
| Narcotic Usage | 1 year | Narcotic usage will be monitored at each follow-up. |
| Presence and Severity of Nausea and Reflux | 1 year | patients will be queried about the presence and severity of nausea and reflux at each follow-up appointment |
| Hospitalizations | 1 year | Pre- and post- intervention hospitalizations will be recorded |
Countries
United States
Outcome results
None listed